

AUSTRALIAN SECURITIES EXCHANGE ANNOUNCEMENT

18 September 2014

The Manager
Companies Announcement Officer
Australian Securities Exchange
Electronic Lodgement

Dear Sir/Madam

ASX RELEASE – PROFIT GUIDANCE

The Board of Directors (“the Board” or “the Directors”) of Asian American Medical Group Limited (“AAMG” or “the Company”) wishes to announce that the Group is expected to report a consolidated group loss for the full year ended 31 August 2014 (“FY 2014”).

The expected net loss in FY 2014 is mainly attributed to, among other reasons, a decline in transplantation cases and patient referrals due to rising costs of associated healthcare in Singapore and increased competition from neighbouring medical tourism centres.

The company is still in the process of finalizing its unaudited financial statements for FY2014. The information contained in this announcement is only a preliminary assessment made by the Board based on currently available information and such information has not been reviewed or audited by the Company’s auditors. Further details of the Group’s performance will be disclosed when the Group announces its financial results for FY2014 on or around 17 October 2014.

On behalf of the Board



DARIO MAZZARI
Company Secretary

About Asian American Medical Group

Asian American Medical Group (“AAMG”) is based in Singapore and has been listed on the Australian Securities Exchange since September 2009. The Group’s operations include the Asian American Liver Centre Pte Ltd (“AALC”), established in 1994 in Singapore, and the Asian American Blood & Marrow Transplant Centre Pte Ltd (“AABMTC”) which opened in 2013.

AALC, one of Asia’s foremost liver centres, is led by renowned hepatobiliary expert and liver transplant surgeon, Dr Tan Kai Chah (Dr K C Tan), who helped start the Liver Transplant Programme at the King’s College Hospital London, UK, and pioneered the highly successful Living Donor Liver Transplantation

For personal use only

(LDLT) Programme in Singapore. In 2014, AALC begun conducting surgical procedures at iHEAL Medical Centre, located in Kuala Lumpur, Malaysia.

AABMTC was established as an extension to AAMG's medical capabilities. It is spearheaded by Dr Yvonne Loh, a Haematologist who specialises in haematopoietic cell transplantation and who has performed close to 100 transplants. Dr Loh also has had specific training in transplant for immunological diseases.

In 2012, AAMG entered into a strategic collaboration with UPMC, one of the top 10 medical institutions in the United States. This has enhanced AAMG's clinical capabilities through shared protocols, rigorous quality standards and technology leading to the establishment of the Comprehensive Transplant Centre – a first-of-its-kind one-stop medical hub for treatment of liver, gastrointestinal and haematological diseases and transplantation in Asia.

For further information, please visit www.aamg.co.

Australia contact:

Mr. Dario Nazzari, Company Secretary

Tel: +61 8 81100999

dario@uhyhn.com.au

Singapore contact (media):

WeR1 Consultants Pte Ltd

Ms Sheryl Sim

Mr Benjamin Cher

Tel : +65 6737 4844

sheryl@wer1.net

Benjamin@wer1.net